Your search for esrd returned 5 results

Keryx Biopharmaceuticals announced results from the Phase 2 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on thrice weekly hemodialysis.

Keryx Biopharmaceuticals announced positive final data from its Phase 3 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis.

BELLUS Health and Celtic Therapeutics announced that a global confirmatory Phase 3 study was initiated for their orphan status drug, Kiacta (eprodisate), for the treatment of Amyloid A (AA) amyloidosis.

Keryx announced results from its Phase 3 trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

Pfizer announced results from two of its Phase 3 studies, ORAL Standard and Oral Step, of tofacitinib (CP-690,550) for the treatment of active rheumatoid arthritis.